Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

142results about How to "Relieve back pain" patented technology

System and Method for Electrical Stimulation of the Lumbar Vertebral Column

Disclosed methods and devices treat chronic lower back pain from degenerated or injured intervertebral discs. Electrodes connected to a pulse generator deliver electrical impulses to nerves located within the posterior longitudinal ligament and annulus fibrosus of lumbar intervertebral discs. The stimulation reduces back pain reversibly, adjustably, and with almost complete coverage of the pain-generating region. A temporary percutaneous lead and a permanent paddle lead are used. The percutaneous lead, designed to prevent inappropriate stimulation of the thecal sac, is inserted using a specially-designed introducer cannula and lead blank. The paddle lead is configured individually for implantation in the anterior epidural space of each patient. Electrical stimulation parameters may also be selected so as to ablate the nerves, using non-thermal irreversible electroporation, or using joule heating wherein a thermal insulator covers substantially all of the thecal sac, thereby shielding the thecal sac from potential heat damage.
Owner:LIPANI JOHN D

Disc shunt delivery devices

The intervertebral disc is avascular. With aging, nutrients and oxygen transporting through the endplates diminish. The disc degenerates, and pain ensues. Delivery devices are used to deliver a conduit through a pedicle or vertebral body into the intervertebral disc to re-establish the exchange of nutrients and waste between the disc and bodily circulation to slow, stop or reverse disc degeneration and relieve pain.
Owner:YEUNG JEFFREY E

System and Methods for Diagnosis and Treatment of Discogenic Lower Back Pain

Methods and devices to treat discogenic lumbar back pain are disclosed. Electrodes are implanted within the anterior epidural space of the patient. A pulse generator that is connected to the electrodes delivers electrical impulses to sympathetic nerves located within the posterior longitudinal ligament (PLL) of the lumbar spine and outer posterior annulus fibrosus of the intervertebral disc. In alternate embodiments, energy directed to nerves in the PLL may be from light or mechanical vibrations, or the nerves may be cooled. The electrodes may also be used diagnostically to correlate spontaneous nerve activity with spinal movement, fluctuations in autonomic tone and the patient's experience of pain. The electrodes may also be used to generate diagnostic evoked potentials. The diagnostic data are used to devise parameters for the therapeutic nerve stimulation. Automatic analysis of the data may be incorporated into a closed-loop system that performs the nerve stimulation automatically.
Owner:LIPANI JOHN D

Medical implant and method of reducing back pain

An expandable medical implant capable of being inserted between adjacent vertebral endplates in a spine. The implant, when in an expanded position, includes a thicker peripheral portion and a thinner interior portion. Also, a method of manufacturing an expandable medical implant having a thicker peripheral portion and a thinner interior portion. Further, a method for reducing back pain that includes placing a medical implant between two adjacent vertebral endplates and positioning the implant such that the implant distributes stresses toward stronger portions of the endplates when pressure is placed on the implant.
Owner:PATEL TUSHAR

Composition to reduce allodynic back pain and related method of use

InactiveUS20110269727A1Maximize resultReduce back painBiocideNervous disorderOpioid antagonistMedetomidine
The invention relates to a pharmaceutical composition to reduce back pain comprising two compounds: an opioid antagonist and a direct-acting alpha 2 adrenegic agonist. The Opioid antagonist is selected from the group consisting of alvimopan, nalmefene, naloxone, naltrexone, methylnaltrexone, nalorphine, and pharmaceutically acceptable salt. The direct-acting alpha 2 adrenegic agonist is selected from a group consisting of Apraclonidine, Brimonidine, Clonidine, Detomidine, Dexmedetomidine, Guanabenz, Guanfacine, Lofexidine, Medetomidine, Romifidine, Tizanidine, Tolonidine, Xylazine and Fadolmidine. In one embodiment, the composition may include naltrexone (or its pharmaceutically acceptable salt) as the opioid antagonist and clonidine hydrochloride (or its pharmaceutically acceptable salt) as the direct-acting alpha 2 adrenegic agonist. It is preferred naltrexone be administered with a second agent such as an antitussive, expectorant, decongestant, or antihistamine. The dosage of naltrexone may range between 0.25 mg to 15 mg, while the dosage of clonidine hydrochloride ranges between 0.0125 mg and 0.3 mg.
Owner:ALLODYNIC THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products